Miranda 1990.

Methods	Study design: parallel RCT Study duration: NS Duration of study: 9 months
Participants	Country: Spain Setting: single centre CAPD; Hb < 8 g/dL Number: treatment group 1 (8); treatment group 2 (7) Mean age ± SD (years): treatment group 1 (44 ± 12); treatment group 2 (56 ± 17): years (SD) Sex (M/F): NS Exclusion criteria: NS
Interventions	Treatment group 1 rHuEPO: SC 20 U/kg/d for 9 months Treatment group 2 rHuEPO: SC 2000 U twice/wk for 9 months Co‐interventions Iron administered; target Hb 10.5 g/dL
Outcomes	Hb levels at the end of the study EPO doses at the end of the study Adverse effects
Notes	Third group given intraperitoneal rHuEPO daily not included
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	NS
Allocation concealment (selection bias)	Unclear risk	Unclear
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Laboratory outcome, unlikely to be influenced by blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Laboratory outcome, unlikely to be influenced by blinding
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear whether all patients completed study
Selective reporting (reporting bias)	High risk	Information provided graphically or for combined groups of patients so could not be included in meta‐analyses
Other bias	Unclear risk	Funding sources NS